Cerus Corporation: FY2015 Form 10-K Summary
Business context and reporting period
Cerus Corporation develops and commercializes the INTERCEPT Blood System, designed to reduce pathogens in donated platelets, plasma and red blood cells. Platelet and plasma systems were commercialized in the United States, Europe, the CIS, the Middle East and selected other markets. The red blood cell system remained in development. This Form 10-K covers the fiscal year ended December 31, 2015; fourth-quarter figures are included where disclosed.
Financial performance and liquidity
| Metric | FY2015 | FY2014 | Change |
|---|---|---|---|
| Revenue | $34.2 million | $36.4 million | Down 6% |
| Gross profit | $10.8 million | $15.2 million | Down 29% |
| Gross margin | 31% | 42% | Down 11 percentage points |
| Research and development | $25.6 million | $21.8 million | Up 18% |
| SG&A | $46.0 million | $37.7 million | Up 22% |
| Loss from operations | $(61.1) million | $(44.5) million | Loss increased |
| Net loss | $(55.9) million | $(38.8) million | Loss increased |
| Diluted loss per share | $(0.61) | $(0.61) | Flat |
| Cash used in operations | $(51.1) million | $(39.8) million | Use increased |
Fourth-quarter 2015 revenue was $9.7 million, gross profit was $3.5 million and net loss was $14.8 million. Cash and cash equivalents were $71.0 million at year-end, compared with $22.8 million in 2014. Short-term investments and marketable equity securities totaled $36.9 million, including an $11.2 million investment in Aduro Biotech. Working capital was $108.5 million.
Total debt was approximately $19.9 million at December 31, 2015, consisting of $20.0 million principal under the Oxford Finance term loan, net of discount. The loan bears interest rates of 6.95% and 7.01% on the drawn tranches, matures in 2019 and is secured by substantially all assets other than intellectual property and 35% of the Cerus Europe investment. A further $10.0 million tranche was available subject to a revenue threshold and other conditions.
Material changes versus the prior comparable period
- Revenue declined despite a 15% increase in disposable platelet and plasma kit unit volume. Management attributed the reported decline primarily to approximately 16% Euro depreciation against the U.S. dollar.
- Gross margin fell to 31% from 42%, reflecting currency effects, approximately $1.8 million of additional obsolescence and manufacturing charges, and higher charges for outdated product.
- R&D and SG&A increased substantially as Cerus funded U.S. commercialization, platelet label-expansion work, illuminator development, infectious-disease IDE studies and the red blood cell program.
- January 2015 equity financing generated approximately $75.3 million of net proceeds and increased shares outstanding to 99.1 million at year-end from 80.4 million.
- Cerus drew the second $10.0 million Oxford Finance tranche in June 2015. No shares were sold under the Cantor at-the-market agreement during 2015.
- All remaining 2010 warrants were exercised in 2015; no warrants remained outstanding at year-end. The company recorded a $3.6 million non-cash warrant revaluation gain.
- Aduro’s 2015 IPO converted Cerus’s preferred shares into 396,700 common shares, creating an $11.2 million marketable equity investment and $7.3 million of unrealized after-tax comprehensive income.
- The amended Fresenius supply agreement eliminated royalties on product sales after June 30, 2015, but created approximately $7.8 million of manufacturing and development obligations at year-end.
Guidance, outlook, commentary and risks
Management expected future revenue growth from broader adoption of platelet and plasma systems, including U.S. commercialization and newly accessible markets, but stated that Cerus expected to continue incurring substantial losses and might never become profitable. The company believed available cash, investments and expected product receipts would fund requirements for at least the next twelve months, subject to assumptions about adoption, spending and capital needs.
Cerus planned to submit the red blood cell system for a European CE mark in the second half of 2016 after completing development, chemistry, manufacturing and controls work. The European chronic-anemia Phase III trial remained ongoing, while additional U.S. development and potentially Phase III trials would be required. Management did not expect regulatory approval of the red blood cell system within the following twelve months.
U.S. adoption remained dependent on blood-center process validation, site-specific FDA licenses, hospital inventory integration, reimbursement and additional FDA approvals for configurations involving 100% plasma, triple-dose collections and random-donor platelets. The FDA had asked questions regarding the 100% plasma PMA supplement.
- Revenue and profitability depend heavily on market adoption of INTERCEPT, particularly in the concentrated U.S. blood-collection market.
- The company relies on Fresenius as the sole manufacturer of disposable kits and relies on other sole or limited-source suppliers for key components, creating supply, quality, cost and regulatory risks.
- Customer concentration is material: Établissement Français du Sang represented 23% of 2015 product revenue.
- Regulatory, clinical and post-approval requirements could delay commercialization or result in loss or restriction of existing approvals.
- Products do not inactivate all pathogens, including prions and certain non-lipid-enveloped viruses, which could constrain adoption.
- Additional financing may be required because operating cash flow remained substantially negative; future equity financing could dilute shareholders and debt financing could impose restrictive covenants.
- Fresenius commitments, debt repayments, inventory requirements and planned clinical and commercialization spending represent significant future cash obligations.
- Foreign exchange volatility, particularly the Euro and CIS currencies, can materially affect reported revenue, margins and operating results.
Most important facts for an investor to verify
- Whether U.S. customer adoption and revenue growth accelerate sufficiently to offset continued operating cash burn.
- The company’s actual cash runway after incorporating debt amortization, Fresenius payments, clinical development and commercialization expenses.
- The timing and outcome of FDA decisions on platelet label expansion and required post-approval studies.
- Progress, safety results, commercial configuration and regulatory submission status of the red blood cell system.
- Final pricing and volume terms under the new Établissement Français du Sang subcontract.
- Dependence on Fresenius and other sole-source suppliers, including qualification of alternate suppliers and potential inventory obsolescence.
- The valuation and volatility of the Aduro investment and its effect on comprehensive income, liquidity and reported tax items.
- Compliance with Oxford Finance covenants and the conditions for accessing the remaining $10.0 million tranche.
- Management’s remediation of previously reported internal-control weaknesses; management and Ernst & Young concluded controls were effective as of December 31, 2015.